Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03857087 · ClinicalTrials.gov registry record
68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer
A clinical trial, sponsored by University of California, San Francisco.
- Completed
- Registry status
- 7
- Enrollment target
NCT03857087 is a clinical trial that has completed, run by University of California, San Francisco. The registered enrollment target is 7 participants.
The verdict
NCT03857087 has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- 7 participants
- Enrollment target
Study Summary
This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a radioactive substance that binds to blood vessels around the ovarian cancer and can be imaged using PET. Diagnostic procedures, such as PET, may help find and diagnose find out how far the disease has spread.
Interventions
- PROCEDURE Magnetic Resonance Imaging (MRI)
- PROCEDURE Positron Emission Tomography (PET)
- DRUG Gallium Ga 68-labeled PSMA-11
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2018-04-02 |
| Est. Completion | 2022-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03857087
The ClinicalTrials.gov registry entry for NCT03857087 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Magnetic Resonance Imaging (MRI) is the first listed.
NCT03857087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03857087 about?
NCT03857087 is a clinical study titled "68Ga-PSMA PET in Diagnosing Metastasis in Patients With Ovarian Cancer". This trial studies how well gallium Ga 68-labeled prostate specific membrane antigen (PSMA)-11 (68Ga-PSMA) positron emission tomography (PET) works in patients with ovarian cancer to detect whether the tumor has spread to other places in the body. 68Ga-PSMA is a radioactive substance that binds to b...
What is the current status of trial NCT03857087?
This trial is currently completed. The enrollment target is 7 participants. The study started on 2018-04-02. Estimated completion is 2022-06-30.
What interventions are being tested in trial NCT03857087?
The interventions under investigation include: Magnetic Resonance Imaging (MRI) (PROCEDURE), Positron Emission Tomography (PET) (PROCEDURE), Gallium Ga 68-labeled PSMA-11 (DRUG).
Who is sponsoring clinical trial NCT03857087?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.